SCHEMBL31358731

SCHEMBL31358731

O=C(O)c1cc(-c2ccc(C=C3C(=O)c4ccccc4C3=O)o2)ccc1Cl

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.77
KMT2A Q03164 12/20 0.71
POLB P06746 10/20 0.71
TDP1 Q9NUW8 9/20 0.71
ALDH1A1 P00352 9/20 0.71
KDM4E B2RXH2 8/20 0.71
L3MBTL1 Q9Y468 8/20 0.71
CTDSP1 Q9GZU7 6/20 0.71
APEX1 P27695 5/20 0.71
PTPN5 P54829 3/20 0.70
MEN1 O00255 9/20 0.67
MAPT P10636 9/20 0.67
PKM P14618 2/20 0.67
GAA P10253 1/20 0.67
RECQL P46063 6/20 0.65
PTPN1 P18031 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
DUSP26 Q9BV47 1/20 0.60
TTR P02766 1/20 0.59
EP300 Q09472 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358841 0.91 AKT1 (0.73) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358662 0.87 AKT1 (1.00) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL6720217 0.87 AKT1 (1.00) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358764 0.87 AKT1 (0.62) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358895 0.86 AKT1 (0.77) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358776 0.85 SIRT2 (0.62) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358892 0.84 ALDH1A1 (0.64) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358669 0.83 PTPN5 (0.63) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL31358693 0.82 AKT1 (0.58) AKT1KMT2APOLBTDP1ALDH1A1
SCHEMBL5164488 0.81 KMT2A (0.71) KMT2APOLBTDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 AKT1 194/4885KMT2A 1043/4885POLB 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.